Hong Kong CHM: The Evolution of Chinese Herbal Medicine in Modern Pharmaceutical Industry
Embarking on a temporal voyage, Hong Kong's Chinese Herbal Medicine Drug Development Center champions the progressive evolution from herbal medicine to modern prescription drugs, bridging the gap between ancient healing practices and the demands of contemporary healthcare.
Nov 28, 2023
OnTarget Study Innovates Cancer Therapy-Related Diarrhea Management with Crofelemer
Napo Pharmaceuticals's pivotal phase 3 OnTarget trial for prophylaxis of diarrhea in adult cancer patients is a 12-week trial targets cancer therapy-related diarrhea. The product emphasizes ethical and sustainable practices and bring new hope in CIOB management by prioritizing patient well-being.
Nov 15, 2023
FDA Approves NexoBrid: Transformative Topical Gel Redefines Burn Care
NexoBrid is a topical gel that removes dead tissue, called eschar, from burns. It's made from proteolytic enzymes enriched in bromelain from pineapple stems. NexoBrid is used to treat adults with deep partial thickness and full thickness thermal burns.
Oct 26, 2023
Botanical Drug for the Treatment of Alopecia Areata in Children
Coacillium, Legacy Healthcare's plant-based remedy, shows promise for alopecia areata, fostering hair regrowth in children per 2023 EADV research. Notably, it sustains remission without immune-altering effects, marking a breakthrough in dermatological care.
Sep 26, 2023
Botanical drug clinical trial: common issues and future options
Abstract: botanical drug clinical trials registered at ClinicalTrial.gov were analyzed. Trends in current trials were discovered and guide future trials was recommended. A total of 195 botanical drug clinical trials were registered from 2016 to 2019, of which 81 are phase II or phase II/III. Most were with 100 or less participants per arm ...
Aug 31, 2023
RCT: Traditional Chinese Medicine Compound (Tongxinluo) for Acute Myocardial Infarction
In patients with ST-segment elevation myocardial infarction (STEMI), the traditional Chinese medicine Tongxinluo, as an adjunctive therapy to guideline-directed treatment, is associated with significantly improved clinical outcomes, according to a study published in the Oct issue of the J of the American Medical Association.
Jul 15, 2023
Alphyn Biologics Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection
Alphyn Biologics, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics, released interim results today from the second cohort of its Phase 2a clinical trial program of AB-101a, a novel topical candidate for atopic dermatitis (AD).
Jul 5, 2023
Baptist University Advanced a Botanical Drug to Phase I
Hong Kong Baptist University is set to conduct the first phase of clinical trials for a novel Chinese medicine targeting chronic constipation in the US, after it gained the US FDA approval to proceed. The medicine, known as CDD-2101, represents a significant milestone as the first botanical drug developed in Hong Kong.
Jun 10, 2023
Plant extracts hold promise in treatment of ataxia
A University team of researchers have discovered that extracts from plants used by the First Nations peoples in their traditional botanical medicine practices are able to rescue the function of ion channel proteins carrying mutations that cause human Episodic Ataxia.
May 2, 2023
Sinoveda's Botanical Drug Approach to Treat Long Covid
Sinoveda is a health brand that is bringing innovative, herbally-based precision to drug discovery, created a patented pharmaceutical platform technology (PPT) used to study herbs with a historical record of efficacy.
Mar 20, 2023
CASE STUDY: Mytesi
A showcase of the first botanical drug approved by the US FDA for treating diarrheal caused by HIV/AIDS antiretroviral therapy, about the what was described for the structure, methods to test and ensure therapeutic consistency, studies of dose response. This set an example for future botanical drug development.
Nov 25, 2022
Napo Pharmaceuticals Submits Investigational New Drug (IND) Application to FDA
Napo Pharmaceuticals Inc announced the submission of an IND application to the U.S. FDA for a new crofelemer powder for oral solution formulation for the treatment of microvillus inclusion disease (MVID).
Nov 9, 2022
Cannabis-derived drug treating lung received $3M seed
RS BioTherapeutics received $3M capital from its second seed round to focus on developing a medication for chronic obstructive pulmonary disease
Sep 23, 2022
REHEVA BIOSCIENCES ANNOUNCES FIRST PATIENT ENROLLED IN RH324 PHASE I SAFETY TRIAL
ReHeva Biosciences is announcing the first patient enrolled and dosed in the Phase I Safety Trial for the company's drug, RH324.
Aug 2, 2022
Paper: Coronavirus disease 2019: The prospect for botanical drug’s polymolecular approach
Abstract: anti‑inflammatory therapies and vaccine approach are not effective in treating viruses. A multi‑target approach has been used with success for human immunodeficiency virus and some types of cancer. It has been recently proposed to use the same strategy for COVID‑19.
Jul 2, 2022
Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective
The United States FDA has received over 800 botanical investigational new drug applications (IND) and pre-IND meeting requests (PIND) in the years preceding 2018. Between 2016 and 2019, 195 botanical drug clinical trials were registered, of which 81 are phase 2. By the end of 2018, over 600 IND applications were in clinical development under the botanical drug category.
Jun 8, 2022
Yeast probiotic designed to treat diarrhea and strengthen healthy digestive and immune systems
The new strain of yeast probiotic developed by a yeast company in China, S. boulardii Bld-3, is ground-breaking addition to the S. boulardii family that has been proven effective in speeding up recovery from acute diarrhea and is beneficial to intestinal health in the long term
May 28, 2022
Yiviva Advances its Botanical Cancer Drug into the Clinical Development
Yiviva, a pharmaceutical company focused on developing botanical drugs, has moved its lead candidate further into an international phase IIb trial for liver cancer and closer to an application through the FDA’s little-used botanicals pathway and a similar pathway in China.
Apr 4, 2022
A third FDA-approved botanical drug is on the horizon
The U.S. Food and Drug Administration (FDA) gave priority review to Amryt Pharma’s application seeking approval of Filsuvez (Oleogel-S10), a topical gel to treat skin wounds in people epidermolysis bullosa (EB).
Mar 21, 2022
Enrichment of ginsenoside (Rg3) from ginseng by post-harvest processing and extraction
Treatment with 0.5 mol/L acetic acid can stimulate the degradation of polar ginsenosides to less polar ginsenosides (5.6% Rg3 was accumulated, P < 0.0001).
Feb 4, 2022
India Starts a Botanical Drug Clinical Trial for Covid-19
Helixmith said it has begun the clinical trials of its natural extract-based Covid-19 drug TADIOS (HX110) with infected patients in India by giving its first dose on Thursday.
Jan 26, 2022
Herb Exocarpium Citri grandis in the prevention and treatment of COVID-19
Huajuhong (Exocarpium Citri grandis, ECG) is a traditional Chinese herbal medicine and has been used for the treatment of respiratory diseases for hundreds of years. Recently, ...
Dec 10, 2021
Chlorogenic acid may be a potent inhibitor of dimeric SARS-CoV-2 main protease 3CLpro
Abstract: Among all the compounds, chlorogenic acid showed druggable characteristics and scored the lowest binding energy with main protease and main peptidase via interacting with active site 1 domain amino acid residues. Interestingly, chlorogenic acid interacted with Phe140 main protease 3CLpro, which is potentially involved in the dimerization.
Nov 25, 2021
WHO ICD-11 includes diagnoses used in Traditional Medicine
The 11th revision of the World Health Organization’s (WHO) International Statistical Classification of Diseases and Related Health Problems (ICD) includes Traditional Chinese Medicine (TCM) for the first time, and will come into effect on January 1, 2022.
Oct 10, 2021
Modelling Bioactivities of Botanical Extracts Using Network Pharmacology and Polypharmacology.
ABSTRACT: Network pharmacology and polypharmacology are emerging as novel drug discovery paradigms. The many discovery, safety and regulatory issues they raise may become tractable with polypharmacological combinations of natural compounds found in whole extracts of edible and mixes thereof.
Oct 6, 2021
Botanical drug is shown to help patients with head and neck cancers
In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are located in the head and the neck.
Sep 27, 2021
CSIR to begin two clinical drug trials to combat COVID-19
The Council for Scientific and Industrial Research (CSIR) has received approval from Drug Controller General of India (DGCI) for its two clinical trial drugs - 'favipiravir' and 'phytopharmaceutical' - to combat coronavirus.
Aug 4, 2021
Phase IIB clinical trial initiated for treating hepatitis B-associated liver cancer
The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer.
Jul 18, 2021
Abstract: Medicinal plants and bioactive natural compounds for cancer treatment
Cancer is one of the largest causes of morbimortality in the world and due to its prevalence the discovery of novel anticancer drugs in of great importance. The past century brought great advances in the field of plant and microbiology research, with the ......
Jun 30, 2021
Batch-to-Batch Quality Consistency Evaluation of Botanical Drug Products Using Multivariate Statistics
ABSTRACT: Botanical drug products have batch-to-batch quality variability due to botanical raw materials and the current manufacturing process. The rational evaluation and control of product quality consistency are essential to ensure the efficacy and safety. Chromatographic fingerprinting is an ...
Apr 4, 2021
Genome-wide Biological Response Fingerprinting as a Potential Metric for Quality Control
ABSTRACT: Quality control plays a critical role in the process of translating the traditional/alternative medicines into modern evidence-based therapies. High performance liquid chromatography (HPLC) is widely ...
Mar 20, 2021
Role of mass spectrometry in establishing safety and efficacy of botanical dietary supplements
As in drug discovery and development, mass spectrometry has become essential at all stages for establishing the safety and efficacy of botanical dietary supplements. Applications of mass spectrometry to the development ...
Feb 25, 2021
Botanical Drug Development: Waiver of Preclinical Pharm/Tox Studies and Importance of Initial Clinic
Development of botanical drug products in the U.S. may be entitled for a waiver of preclinical Pharm/Tox (P/T) studies prior to an initial clinical trial, contingent upon existing previous human experience.
Jan 5, 2021
Merging Traditional Chinese Medicine with Modern Drug Discovery Technologies to Find Novel Drugs
Traditional Chinese Medicines (TCM) are rapidly gaining attention in the West as sources of new drugs, dietary supplements and functional foods. However, ...
Dec 25, 2020
Multiple chromatographic fingerprinting and its application to the quality control of herbal medicin
Recently, chromatographic fingerprinting has become one of the most powerful approaches to quality control of herbal medicines. However, the performance of reported chromatographic fingerprinting constructed by single chromatogram sometimes turns out to be inadequate for complex herbal medicines, ...
Nov 10, 2020
EU regulatory and Quality Requirements for Botanical Drugs and Their Implications
Regulatory pathways and characteristic quality requirements for marketing authorization of herbal medicinal products in the European Union（EU), and the legal status and applications of "European Union list of herbal substances, preparations and combinations" and "European Union herbal monographs".
Oct 25, 2020
Botanical Drug Development and Quality Standards
In 2015 a draft Guidance for Industry: Botanical Drug Development. The draft revised botanical guidance provides additional recommendations on quality, nonclinical, clinical, and other unique aspects associated botanical drug development.
Sep 4, 2020
The Development of Botanical Drugs – A Review
History and evaluation of developing medicines from plants
Aug 26, 2020
Tetra Bio-Pharma: building business on healing cannabinoid medicines
Canada’s Tetra Bio-Pharma is on a path to become a world leader in the development of cannabinoid-derived medicines, with several promising drugs undergoing advanced clinical trials.
Jul 7, 2020
New 'non-invasive' cancer treatment 'targets and destroys' 80% of tumor cells
Israeli researchers have succeeded in destroying breast cancer cells after developing a new treatment that "combines the application of low-frequency ultrasound and microbubbles," Tel Aviv University's Department of Biomedical Engineering announced on Thursday.
Jun 23, 2020
Yale Medicine: Herbal Medicine Unlocks New Possibilities for Cancer Treatment
Now, in a landmark moment in cancer research, Cheng and research partners are launching the first international clinical trial for a botanical drug, YIV-906. The trial, involving patients with liver cancer and hepatitis B, will take place at 20 institutions across the United States, China, Taiwan, and Hong Kong. Lead sites include Memorial Sloan Kettering and Northwell Health Cancer ...
May 7, 2020
A New Pharma Initiative takes on the Antibiotic Innovation Challenge
Pfizer, Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Bayer Pharmaceuticals, Merck are teaming up to create an initial $1 billion for-profit venture to bet on small biotechs developing mid-stage antibiotics.
Apr 5, 2020
FDA Approves First Drug Derived from Marijuana to Treat Epilepsy
(cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.
Mar 20, 2020
THC microdosing reduces chronic pain in world-first clinical trial
Israeli pharma-tech company, Syqe Medical, set out to test a first-of-its-kind product that reportedly enables precise dosing of low-levels of THC to control pain.
Feb 6, 2020
COVID-19 IND Moves to Phase 2
An Ivestigational New Drug Application (IND) for the use of FSD201 (ultramicronized palm itoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus (the "FSD201 COVID-19 Trial") was announced by FSD Pharma Inc.
Jan 21, 2020
Patients Recovered from Covid-19 May Still Face Lasting Organ Damage
Research published Friday in a journal, "JAMA Cardiology", found that 4 out of 26 college athletes had signs of a heart condition called myocarditis after recovering from COVID-19.
Nov 21, 2019
First Covid-19 Treatment Drug Remdesivir Approved by FDA
The US Food and Drug Administration has approved remdesivir for the treatment of coronavirus infection, the drug's maker, Gilead Sciences.
Sep 21, 2019
FDA issued 123 "warning letters" in 2020 to dietary supplement companies for Covid19 Claims
By the end of Oct 2020, FDA issued 123 first-time warning letters this year to dietary supplement companies regarding unapproved and misbranded products related to covid19. Those products are herbal products and hemp products marketed online and on social media networks.
Aug 4, 2019
Developing Medicine from Ancient Herbal Medicine to Treat Cancer
University of Houston professor of pharmaceutics Ming Hu is developing and testing an ancient Chinese herbal medicine formula, first described in 280 A.D., to improve cancer therapy.
Jul 24, 2019
GW Pharma Develops a Botanical Drug to Treat Multiple Sclerosis
California-based GW said it will launch the first Phase III trial studying nabiximols, which is known as Sativex outside the United States, as a potential treatment for multiple sclerosis-associated spasticity.
Jun 2, 2019
FTC sanctions CBD manufactures for misleading medical claims
The U.S. Federal Trade Commission announced its first crackdown on deceptive claims in the CBD market Thursday, issuing fines and sanctions to six manufacturers accused of misleading consumers about the health benefits of the cannabis extract.
May 27, 2019